Original article

Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia

F. Giona, A. M. Testi, S. Amadori, G. Meloni, M. Carotenuto, L. Resegotti, R. Colella, P. Leoni, A. M. Carella, P. Grotto, R. Miniero, F. Mandelli

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Summary: Between August 1985 and April 1989, 88 patients (31 children and 57 adults) with refractory of relapsed acute lymphoblastic leukemia (ALL) were treated in a cooperative Italian trial by an induction schedule of high-dose Cytarabine (HDAra-C) plus Idarubicin (IDA). Complete remission (CR) was achieved in 52 of the 88 patients (59%); 23 patients (26%) did not respond to treatment and 13 (15%) died during induction. The CR rate was significantly affected by the WBC count at the beginning of treatment and by the duration of first CR of the patients treated at first relapse. All of the patients experienced profound myelosuppression; the median time to recovery to neutrophils > 0.5 ×10 9/l was 15 days (range 4-40), and 14 days (range 3-50) to platelets > 50 × 109/l. The most common non-hematologic side effects observed were nausea and vomiting (51%), mucositis (40%) and diarrhea (23%). Twenty-one of the 52 patients who achieved CR underwent bone marrow transplantation (BMT), 16 autologous and 5 allogeneic. Eleven patients relapsed at a median of 4 months (range 1-31) after the transplantation, and three patients died while in CR. Seven patients have been in continuous CR (CCR) for a median of 36 months (range 26-42 months). Thirty-one patients were not entered in the BMT program: for two adults it was too early, three adults died in CR and 25 patients relapsed at a median of four months (range 1-25). Only one adult is still in CCR at 33 months. The authors feel that a less toxic induction therapy followed by a consolidation regimen with non-cross resistant drugs, and by BMT, might achieve an improved control of the disease in this very high risk population.

Original languageEnglish
Pages (from-to)51-55
Number of pages5
JournalAnnals of Oncology
Volume1
Issue number1
Publication statusPublished - 1990

Fingerprint

Idarubicin
Cytarabine
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute
Refractory materials
Dose
Bone
Transplantation
Proof by induction
Range of data
Platelets
Consolidation
Bone Marrow Transplantation
Therapeutics
Neutrophils
Nausea
Vomiting
Recovery
Therapy

Keywords

  • Acute lymphoblastic leukemia
  • Bone marrow transplantation
  • Chemotherapy
  • Idarubicin

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Giona, F., Testi, A. M., Amadori, S., Meloni, G., Carotenuto, M., Resegotti, L., ... Mandelli, F. (1990). Original article: Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Annals of Oncology, 1(1), 51-55.

Original article : Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. / Giona, F.; Testi, A. M.; Amadori, S.; Meloni, G.; Carotenuto, M.; Resegotti, L.; Colella, R.; Leoni, P.; Carella, A. M.; Grotto, P.; Miniero, R.; Mandelli, F.

In: Annals of Oncology, Vol. 1, No. 1, 1990, p. 51-55.

Research output: Contribution to journalArticle

Giona, F, Testi, AM, Amadori, S, Meloni, G, Carotenuto, M, Resegotti, L, Colella, R, Leoni, P, Carella, AM, Grotto, P, Miniero, R & Mandelli, F 1990, 'Original article: Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia', Annals of Oncology, vol. 1, no. 1, pp. 51-55.
Giona, F. ; Testi, A. M. ; Amadori, S. ; Meloni, G. ; Carotenuto, M. ; Resegotti, L. ; Colella, R. ; Leoni, P. ; Carella, A. M. ; Grotto, P. ; Miniero, R. ; Mandelli, F. / Original article : Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. In: Annals of Oncology. 1990 ; Vol. 1, No. 1. pp. 51-55.
@article{9ad3708d20ee4599bcde0e080430bc4c,
title = "Original article: Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia",
abstract = "Summary: Between August 1985 and April 1989, 88 patients (31 children and 57 adults) with refractory of relapsed acute lymphoblastic leukemia (ALL) were treated in a cooperative Italian trial by an induction schedule of high-dose Cytarabine (HDAra-C) plus Idarubicin (IDA). Complete remission (CR) was achieved in 52 of the 88 patients (59{\%}); 23 patients (26{\%}) did not respond to treatment and 13 (15{\%}) died during induction. The CR rate was significantly affected by the WBC count at the beginning of treatment and by the duration of first CR of the patients treated at first relapse. All of the patients experienced profound myelosuppression; the median time to recovery to neutrophils > 0.5 ×10 9/l was 15 days (range 4-40), and 14 days (range 3-50) to platelets > 50 × 109/l. The most common non-hematologic side effects observed were nausea and vomiting (51{\%}), mucositis (40{\%}) and diarrhea (23{\%}). Twenty-one of the 52 patients who achieved CR underwent bone marrow transplantation (BMT), 16 autologous and 5 allogeneic. Eleven patients relapsed at a median of 4 months (range 1-31) after the transplantation, and three patients died while in CR. Seven patients have been in continuous CR (CCR) for a median of 36 months (range 26-42 months). Thirty-one patients were not entered in the BMT program: for two adults it was too early, three adults died in CR and 25 patients relapsed at a median of four months (range 1-25). Only one adult is still in CCR at 33 months. The authors feel that a less toxic induction therapy followed by a consolidation regimen with non-cross resistant drugs, and by BMT, might achieve an improved control of the disease in this very high risk population.",
keywords = "Acute lymphoblastic leukemia, Bone marrow transplantation, Chemotherapy, Idarubicin",
author = "F. Giona and Testi, {A. M.} and S. Amadori and G. Meloni and M. Carotenuto and L. Resegotti and R. Colella and P. Leoni and Carella, {A. M.} and P. Grotto and R. Miniero and F. Mandelli",
year = "1990",
language = "English",
volume = "1",
pages = "51--55",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Original article

T2 - Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia

AU - Giona, F.

AU - Testi, A. M.

AU - Amadori, S.

AU - Meloni, G.

AU - Carotenuto, M.

AU - Resegotti, L.

AU - Colella, R.

AU - Leoni, P.

AU - Carella, A. M.

AU - Grotto, P.

AU - Miniero, R.

AU - Mandelli, F.

PY - 1990

Y1 - 1990

N2 - Summary: Between August 1985 and April 1989, 88 patients (31 children and 57 adults) with refractory of relapsed acute lymphoblastic leukemia (ALL) were treated in a cooperative Italian trial by an induction schedule of high-dose Cytarabine (HDAra-C) plus Idarubicin (IDA). Complete remission (CR) was achieved in 52 of the 88 patients (59%); 23 patients (26%) did not respond to treatment and 13 (15%) died during induction. The CR rate was significantly affected by the WBC count at the beginning of treatment and by the duration of first CR of the patients treated at first relapse. All of the patients experienced profound myelosuppression; the median time to recovery to neutrophils > 0.5 ×10 9/l was 15 days (range 4-40), and 14 days (range 3-50) to platelets > 50 × 109/l. The most common non-hematologic side effects observed were nausea and vomiting (51%), mucositis (40%) and diarrhea (23%). Twenty-one of the 52 patients who achieved CR underwent bone marrow transplantation (BMT), 16 autologous and 5 allogeneic. Eleven patients relapsed at a median of 4 months (range 1-31) after the transplantation, and three patients died while in CR. Seven patients have been in continuous CR (CCR) for a median of 36 months (range 26-42 months). Thirty-one patients were not entered in the BMT program: for two adults it was too early, three adults died in CR and 25 patients relapsed at a median of four months (range 1-25). Only one adult is still in CCR at 33 months. The authors feel that a less toxic induction therapy followed by a consolidation regimen with non-cross resistant drugs, and by BMT, might achieve an improved control of the disease in this very high risk population.

AB - Summary: Between August 1985 and April 1989, 88 patients (31 children and 57 adults) with refractory of relapsed acute lymphoblastic leukemia (ALL) were treated in a cooperative Italian trial by an induction schedule of high-dose Cytarabine (HDAra-C) plus Idarubicin (IDA). Complete remission (CR) was achieved in 52 of the 88 patients (59%); 23 patients (26%) did not respond to treatment and 13 (15%) died during induction. The CR rate was significantly affected by the WBC count at the beginning of treatment and by the duration of first CR of the patients treated at first relapse. All of the patients experienced profound myelosuppression; the median time to recovery to neutrophils > 0.5 ×10 9/l was 15 days (range 4-40), and 14 days (range 3-50) to platelets > 50 × 109/l. The most common non-hematologic side effects observed were nausea and vomiting (51%), mucositis (40%) and diarrhea (23%). Twenty-one of the 52 patients who achieved CR underwent bone marrow transplantation (BMT), 16 autologous and 5 allogeneic. Eleven patients relapsed at a median of 4 months (range 1-31) after the transplantation, and three patients died while in CR. Seven patients have been in continuous CR (CCR) for a median of 36 months (range 26-42 months). Thirty-one patients were not entered in the BMT program: for two adults it was too early, three adults died in CR and 25 patients relapsed at a median of four months (range 1-25). Only one adult is still in CCR at 33 months. The authors feel that a less toxic induction therapy followed by a consolidation regimen with non-cross resistant drugs, and by BMT, might achieve an improved control of the disease in this very high risk population.

KW - Acute lymphoblastic leukemia

KW - Bone marrow transplantation

KW - Chemotherapy

KW - Idarubicin

UR - http://www.scopus.com/inward/record.url?scp=0024988943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024988943&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 51

EP - 55

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -